Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Related Resources

Related Resources

Customizing structured data collection with mint Lesion™ Template Editor

We are thrilled to announce a forthcoming addition to mint Lesion™: the Template Editor. This feature will transform the way users interact with our…

Improving Cancer Care Through Standardization: Interview with Prof. Thomas Kröncke on the BZKF Project BORN

The Bavaria-wide oncological radiology network (BORN) Project was launched on August 1, 2022, with the objective of improving cancer care in Bavaria…

Optimizing Clinical Trials without Compromising Patient Care: An Investigational Site’s Perspective

Attracting and retaining industry-sponsored clinical trials can be quite appealing for healthcare institutions. Besides obvious financial and…